Consistent with the inhibitory effects of linsitinib on cell proliferation (Fig 1A), pretreatment with 1–20 μM linsitinib significantly reduced IGF-increased the proportion of S-phase cells in OFs from TAO patients (Figs 2A and S1D). This evidence concerns the gene IGF1 and thromboangiitis obliterans.